NONCOMPLIANCE WITH STATIN THERAPY
OUTCOMES AND COSTS OF ISCHEMIC COMPLICATIONS AND BLEEDING IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS
LONG-TERM COSTS AND CLINICAL CONSEQUENCES OF DIFFERENT LEVELS OF 2-HOUR POST PRANDIAL BLOOD GLUCOSE IN NON-DIABETES PATIENTS
CORRELATION BETWEEN NEW YORK HEART ASSOCIATION CLASSIFICATION AND PATIENT-REPORTED OUTCOMES
A ROBUST GLOBAL TREATMENT RESPONSE AVAILABLE TO OLANZAPINE-TREATED PATIENTS IS ASSOCIATED WITH MEANINGFUL IMPROVEMENT IN NEGATIVE SYMPTOMS AND QUALITY OF LIFE
COMPARISON OF TREATMENT COST FOR DEPRESSION BETWEEN FLUOXETINE, PAROXETINE, SERTRALINE AND VENLAFAXINE USING MANAGED CARE CLAIMS DATA
DEPRESSION IN PRIMARY CARE
ECONOMIC IMPACT OF TREATMENT OF DEMENTIA FOR GERMANY—A PROGNOSES TO 2050
THE VALUE OF MULTIPLE YEARS HISTORY IN IDENTIFYING COMORBID CONDITIONS IN A RETROSPECTIVE DATA ANALYSIS
QOL INDICATORS OF SATISFACTION AND IMPACT ASSOCIATED WITH WEB-ENABLED DIABETES SELF-MANAGEMENT TOOLS
DIABETIC FOOT ULCERS
A SYSTEMATIC ANALYSIS OF CONCOMITANT MORBIDITY AND MORTALITY IN DIABETES
META-ANALYSIS OF UTILITY ESTIMATES
VALUE OF INFORMATION ANALYSIS OF THE DECISION BETWEEN CIPROFLOXACIN VS. TRIMETHOPRIM SULPHAMETHOXAZOLE FOR EMPIRICAL TREATMENT OF WOMEN WITH PYELONEPHRITIS
COST-EFFECTIVENESS OF NEW RAPID SCREENING TECHNOLOGIES FOR GONORRHEA IN URBAN EMERGENCY ROOM DEPARTMENTS
THE COST OF ANTIRETROVIRAL THERAPY IN THREE CENTRAL AMERICAN COUNTRIES
HANDLING MISSING DATA IN STOCHASTIC COST-EFFECTIVENESS ANALYSIS
COST-EFFECTIVENESS VS. COST-UTILITY ANALYSIS
IMPORTANCE OF CONSIDERING SENSITIVITY AND SPECIFICITY OF SCREENING METHODS IN HEALTH ECONOMIC ANALYSES OF DIABETIC NEPHROPATHY SCREENING POLICIES
THE DANGER OF IGNORING POPULATION HETEROGENEITY WHEN MARKOV MODELS ARE USED FOR COST EFFECTIVENESS ANALYSIS
SUB-OPTIMAL STATIN COMPLIANCE IN PRIMARY AND SECONDARY PREVENTION POPULATIONS
IS IT COST-EFFECTIVE TO IMPROVE COMPLIANCE WITH LIPID-LOWERING THERAPY?
IMPROVING THE SAFETY OF AMIODARONE IN THE CONGESTIVE HEART FAILURE POPULATION
THE IMPACT OF ADHERENCE TO OSTEOPOROSIS THERAPY ON FRACTURE RATES IN ACTUAL PRACTICE
COST-EFFECTIVENESS OF STATINS IN PRIMARY PREVENTION OF CHD
COMPARING RECENT CARDIOVASCULAR MEDICATIONS USING AN NNT MODEL
COST-EFFECTIVENESS OF ADENOSINE AND DIPYRIDAMOLE IN TECHNETIUM-99M SESTAMIBI SINGLE PHOTON COMPUTED TOMOGRAPHY IMAGING
FORMULARY DECISIONS
ECONOMIC EVALUATION OF CAPECITABINE-DOCETAXEL COMBINATION TREATMENT OF METASTATIC BREAST CANCER
COST-UTILITY ANALYSIS OF LHRH AGONISTS IN THE TREATMENT OF METASTATIC PROSTATE CANCER
BEHIND THE VEIL OF IGNORANCE
COMPARISON OF TREATMENT MODALITIES IN PROSTATE CANCER PATIENTS
EXPLORING THE DERIVATION OF UTILITY VALUES USING A DISCRETE-CHOICE CONJOINT ANALYSIS METHOD—A COST-UTILITY ANALYSIS OF GEMCITABINE PLUS CISPLATIN FOR THE TREATMENT OF BLADDER CANCER
ARE THE FRAMINGHAM-RISK EQUATIONS VALID FOR EUROPE?
HOSPITAL-SPECIFIC RELATIVE INTENSITY SCORES FOR PHARMACEUTICAL SERVICES
DEVELOPING A QUALITY APPRAISAL INSTRUMENT TO EVALUATE THE PEDIATRIC HEALTH ECONOMICS LITERATURE
THE RELATIONSHIP OF DIRECT-TO-CONSUMER ADVERTISING AND CLINICIAN BEHAVIORAL INTENTIONS
RELATIONSHIP OF DIRECT-TO-CONSUMER ADVERTISING SPENDING AND DRUG PRICING FOR THE TOP TWENTY DRUGS FROM 1997 TO 2000
IMPACT OF DIRECT TO CONSUMER ADVERTISING—THE CONSUMER SEARCH FOR INFORMATION
FDA REGULATORY ACTIONS AGAINST MISLEADING OR UNSUBSTANTIATED ECONOMIC AND QUALITY-OF-LIFE CLAIMS
RELATIONSHIP BETWEEN DIFFERENT MEASURES OF ASTHMA SEVERITY
DIRECTLY ELICITED PREFERENCES COMPARED TO PREFERENCES DERIVED FROM THE SF-36 IN ADULT ASTHMATICS
MOXIFLOXACIN IV/PO MONOTHERAPY IS COST-EFFECTIVE TO THE GERMAN AND FRENCH HEALTHCARE SYSTEMS WHEN COMPARED TO IV/PO AMOXICILLIN/CLAVULANATE ± CLARITHROMYCIN IN THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA
PSYCHOMETRIC PROPERTIES OF THE ACUTE BRONCHITIS SYMPTOM SEVERITY SCALE IN AN INTERNATIONAL SAMPLE
INDIRECT COSTS DUE TO BACK PAIN IN THE UNITED STATES
EXCESSIVE COSTS RESULTING FROM PRIMARY CARE AND CHIROPRACTIC UTILIZATION OF DIAGNOSTIC IMAGING IN THE FIRST WEEK OF CARE FOR ACUTE LOW BACK PAIN
AN ITEM ANALYSIS OF THE 24 HOUR HEADACHE DISABILITY QUESTIONNAIRE (DISQ-24) USING CLASSICAL TEST THEORY AND ITEM RESPONSE THEORY METHODS
TOTAL HEALTHCARE EXPENDITURES FOR MIGRAINE PATIENTS ASSOCIATED WITH CHOICE OF DRUG THERAPY
AN ANALYSIS OF A HEALTHY START SMOKING CESSATION PROGRAM
THE EFFECT OF PREFERRED DRUG STATUS ON PATIENT SWITCHING, ADHERENCE, AND DAYS OF THERAPY
ASSESSING FRACTURE RISK WITH PRESCRIPTION DRUGS IN MEDICARE-ELIGIBLE PLAN MEMBERS OF A TELECOMMUNICATIONS COMPANY
GENERIC NARROW THERAPEUTIC INDEX DRUG USE
IMPACT OF MULTI-TIERED PHARMACY BENEFITS ON MEDICATION ADHERENCE
AN ANALYSIS OF THE EFFECT OF MANAGED CARE IMPLEMENTATION ON PRESCRIPTION DRUG UTILIZATION BY TEXAS MEDICAID CLIENTS
HORIZONTAL INEQUITY IN HEALTH CARE UTILIZATION IN JAPAN
PERCEPTIONS OF COUNSELING FOR OBESITY AND RELATED BARRIERS AMONG COMMUNITY PHARMACISTS IN TEXAS
STRATEGIES TO REDUCE PREVENTABLE DRUG-RELATED MORBIDITY
USE OF HEALTH OUTCOMES DATA IN PROMOTIONAL MATERIALS
A DESCRIPTION OF DISCARDED PRESCRIPTION DRUGS
CHANGING DRUG SELLER BEHAVIOR ON CHILD DIARRHEA MANAGEMENT
THE ROLE OF VARIOUS FACTORS IN THE DRUG FORMULARY DECISION-MAKING PROCESS
IMPACT OF MULTI-TIERED PHARMACY BENEFITS ON PATIENT ATTITUDES AND BEHAVIOR
SURVIVAL RATES FOR PATIENTS RECEIVING TRANSFUSIONS IN THE UNITED STATES FROM AN ADMINISTRATIVE MANAGED CARE DATABASE
PATIENT SATISFACTION AND PHARMACEUTICAL OUTPATIENT CARE
DRUG INSURANCE TYPE AND INAPPROPRIATE PRESCRIPTIONS FOR THE ELDERLY
STOP
MEDICATION SUPPORT PROGRAM IMPROVES MEDICATION COMPLIANCE
SURVIVAL ANALYSIS IN SEDATED INTENSIVE CARE UNIT (ICU) PATIENTS
THERAPEUTIC INTERCHANGEABILITY OF LEVOTHYROXINE
USING THE AMERICAN PRODUCTIVITY AUDIT (APA) TO INFORM EMPLOYERS ABOUT THE WORK-RELATED COST OF HEALTH CONDITIONS IN THEIR WORKFORCE
PREVENTABLE DRUG-RELATED MORBIDITY AND MORTALITY IN OLDER ADULTS
PHARMACY BENEFIT RESOURCE UTILIZATION BY ENROLLEES OF A PUBLIC EMPLOYEES INDEMNITY INSURANCE PROGRAM FOR FIVE FISCAL YEARS FROM 1996 TO 2001
WORK-RELATED COST OF EPISODIC AND CHRONIC-EPISODIC HEALTH CONDITIONS IN THE UNITED STATES
COST-EFFECTIVENESS OF SCREENING DONATED BLOOD WITH MINIPOOL NUCLEIC ACID TESTING (NAT) FOR HEPATITIS B VIRUS (HBV), HEPATITIS C VIRUS (HCV), AND HUMAN IMMUNODEFICIENCY VIRUS (HIV)
IMPACT OF A 3-TIER PHARMACY BENEFIT ON UTILIZATION PATTERNS OF TOP 10 THERAPEUTIC CLASSES
INTER-INSTITUTIONAL VARIABILITY IN PHARMACY COSTS, LENGTH OF STAY AND MORTALITY ASSOCIATED WITH CARDIAC TRANSPLANTATION AT ACADEMIC HEALTH CENTERS
EVALUATION OF DRUGS IN A THREE-TIER PRESCRIPTION DRUG BENEFIT CO-PAYMENT PRICING STRUCTURE
PRACTICAL ASPECTS OF DESIGNING AND CONDUCTING PHARMACOECONOMIC STUDIES IN JAPAN
OUTCOMES AND COSTS OF ACUTE TREATMENT OF TRAUMATIC BRAIN INJURY
PATIENT WILLINGNESS TO PAY FOR COGNITIVE PHARMACY SERVICES IN AMBULATORY CARE SETTINGS
POLISH GUIDELINES FOR CONDUCTING BUDGET IMPACT ANALYSIS IN THEIR COMPARISON TO EXISTING GUIDANCE ON BUDGET IMPACT ANALYSIS IN OTHER COUNTRIES
ECONOMICS OF TRANSFUSION
ANALYZING THE CLINICAL, ECONOMIC, AND POLICY IMPACT OF INDIVIDUALIZED MEDICINE BASED ON GENETIC INFORMATION (“PHARMACOGENOMICS”)
COST EFFECTIVENESS ANALYSIS OF PHARMACEUTICAL CARE IN A MEDICARE DRUG BENEFIT PROGRAM
GENERIC PRESCRIBING INDEX
IMPACT OF SELECTED CONDITIONS ON THE COSTS OF ACCIDENTS AND INJURIES
IMPACT OF AN INCREASE IN PRESCRIPTION CO-PAYMENT ON DRUG UTILIZATION
COST EFFECTIVENESS OF PATHOGEN INACTIVATION IN PLATELET TRANSFUSIONS
VALUE OF VACCINATION
AN EPIDEMIOLOGICAL EXAMINATION OF MEDICATION RESOURCE USE AND COSTS AMONG THE INSURED ELDERLY
FACTORS ASSOCIATED WITH OUT-OF-POCKET PRESCRIPTION DRUG COSTS
HOW MUCH DOES IT COST TO DIE OF THAT? EFFECTS OF AGE AND CHRONIC ILLNESS ON HEALTHCARE COSTS AT THE END OF LIFE
A DECISION ANALYSIS MODEL FOR SCREENING OF HEREDITARY HEMOCHROMATOSIS
A COST-BENEFIT ANALYSIS OF AN INPATIENT, PHARMACY-MANAGED MEDICATION ASSISTANCE PROGRAM FOR INDIGENT PATIENTS
CHILDREN IN NEED OF PHARMACARE
COST SENSITIVENESS AND PHYSICIAN TREATMENT CHOICES
WITHDRAWN
HEALTH-RELATED QUALITY OF LIFE IN HEMOPHILIA AND VON WILLEBRAND'S DISEASE
IMPROVED QUALITY OF LIFE AND DECREASED USE OF HEALTHCARE RESOURCES ARE MAINTAINED DURING 3 YEARS OF GROWTH HORMONE (GH) SUBSTITUTION IN HYPOPITUITARY ADULTS WITH GH DEFICIENCY
A RANDOMIZED, OPEN-LABEL PREFERENCE STUDY OF GENGRAF® COMPARED TO NEORAL® IN STABLE SOLID-ORGAN TRANSPLANT RECIPIENTS
STUDY OF SF-36V.2 IN A MONTANA NATIVE AMERICAN POPULATION
PREVENTABLE DRUG-RELATED MORBIDITY IN OLDER ADULTS IN NOVA SCOTIA, CANADA
CONTENT ANALYSIS OF QUALITY OF LIFE AND PHARMACOECONOMIC MESSAGES IN PHARMACEUTICAL PRODUCT ADVERTISEMENTS
EFFICACY OF AMLODIPINE IN REDUCING SYSTOLIC BLOOD PRESSURE
ADVERSE EVENTS IN CABG TRIALS
A RETROSPECTIVE, OBSERVATIONAL COHORT STUDY OF THE EFFECTS OF STATIN THERAPY ON LIPID LEVELS IN A NATURALISTIC SETTING
TRENDS IN THE ATTAINMENT OF CHOLESTEROL TREATMENT GOALS
ESTIMATING THE IMPACT OF ANTICOAGULATION QUALITY ON EVENT RATES
IMPACT OF PHARMACIST-MANAGED AMBULATORY LIPID CLINIC
AN ANALYSIS OF SCREENING RATES FOR HYPERLIPIDEMIA AMONG MANAGED CARE PLAN MEMBERS PREVIOUSLY HOSPITALIZED FOR CORONARY HEART DISEASE
CLINICAL AND ECONOMIC IMPACTS OF PHARMACIST-MANAGED ANTICOAGULATION MONITORING SERVICES
ASSESSING RISK REDUCTION AND NNT AMONG TYPE 2 DIABETICS TREATED WITH FIBRIC ACID DERIVATIVES
BLOOD PRESSURE REDUCTION AND GAINS IN LIFE EXPECTANCY BASED UPON A MARKOV MODEL OF PRIMARY AND SECONDARY CARDIOVASCULAR EVENTS
THE COST OF WARFARIN MONITORING IN ANTICOAGULATION CLINICS
IMPACT OF ATRIAL FIBRILLATION ON RESOURCE UTILIZATION AND COSTS IN PATIENTS WITH UNDERLYING CARDIOVASCULAR DISEASES
HOSPITAL TREATMENT PATTERNS AND RESOURCE UTILIZATION IN CONGESTIVE HEART FAILURE PATIENTS
COST-EFFECTIVENESS OF THROMBOPROPHYLAXIS IN ACUTELY-ILL MEDICAL INPATIENTS
TOTAL DIRECT MEDICAL AND DRUG COSTS OF NON-ADHERENCE TO STATIN THERAPY WITHIN THE FIRST YEAR OF TREATMENT
DIFFERENCES IN HOSPITAL LENGTH-OF-STAY, CHARGES AND MORTALITY IN CONGESTIVE HEART FAILURE PATIENTS
COST-EFFECTIVENESS OF RAMIPRIL (ALTACE) IN PATIENTS POST-REVASCULARIZATION
OVERWEIGHT AND OBESITY
THE COST-EFFECTIVENESS ANALYSIS OF ASPIRIN FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE
A COST-EFFECTIVENESS ANALYSIS OF STATIN THERAPY IN A MANAGED CARE POPULATION
COST-EFFECTIVENESS OF THE FIBRATES IN THE REDUCTION OF CORONARY HEART DISEASE EVENTS
AN EVALUATION OF THE CLINICAL AND ECONOMIC OUTCOMES ASSOCIATED WITH SWITCHING HYPERLIPIDEMIC PATIENTS TO PREFERRED STATIN THERAPY IN THE U.S. DEPARTMENT OF DEFENSE
THE EFFECT OF β-BLOCKER AND ACE INHIBITOR THERAPY ON THE RISK OF HOSPITALIZATION AND RESOURCE UTILIZATION AMONG PATIENTS WITH CHF ENROLLED IN A MANAGED CARE ORGANIZATION
APPLICATION OF THE COST OF OBESITY MODEL FOR COST BENEFIT ANALYSIS (CBA) OF SIBUTRAMINE AND ORLISTAT
THE ECONOMIC IMPACTS OF TROUGH
FIRST RUSSIAN EXPERIENCE OF ASSESSING WILLINGNESS TO PAY
HEALTH ECONOMIC ASSESSMENT OF THE ARCTIC SUN™ MODEL 100 FOR TEMPERATURE MANAGEMENT IN OFF-PUMP CORONARY ARTERY BYPASS SURGERY
A COST ANALYSIS OF “BRIDGING THERAPY” FOR PATIENTS REQUIRING INTERRUPTION OF CHRONIC ANTICOAGULATION
INFLUENCE OF COMORBID CONDITIONS IN THE HOSPITALIZATION OF ANGINA PATIENTS
ECONOMIC EVALUATION OF THREE MARKET LEADING HMG-CO-A REDUCTASE INHIBITORS
COST-EFFECTIVENESS ANALYSIS OF THE ARCTIC SUN™ MODEL 100 FOR TEMPERATURE MANAGEMENT IN OFF-PUMP CORONARY ARTERY BYPASS SURGERY
COST OF ILLNESS AND RESOURCE UTILIZATION FOR PATIENTS SUFFERING MYOCARDIAL INFARCTION, WITH AND WITHOUT DEPRESSION
QUALITY OF LIFE QUESTIONNAIRES VALIDATION IN ESSENTIAL HYPERTENSIVES FROM AN ECONOMICALLY DISADVANTAGED COMMUNITY
PATTERNS OF ANTIHYPERTENSIVE DRUG UTILIZATION AND CLINIC VISITS FOR ESSENTIAL HYPERTENSION
AN ASSESSMENT OF THE POTENTIAL UK POPULATION OF PEOPLE WITH TYPE 2 DIABETES ELIGIBLE FOR PROPHYLAXIS WITH RAMIPRIL TO PREVENT CARDIOVASCULAR EVENTS
MEDICATION ADHERENCE AND HEALTH CARE UTILIZATION IN HEART FAILURE PATIENTS
EFFECT OF NON-ADHERENCE TO STATINS ON ASSOCIATED COST EFFECTIVENESS
MORE MEDICATIONS AND DISEASE STATES WERE RELATED TO AN INCREASE IN MEDICATION ADHERENCE AMONG PATIENTS AFTER A MYOCARDIAL INFARCTION
CARDIORENAL EFFECTS AND COSTS OF COX-2 INHIBITORS IN A MANAGED CARE ORGANIZATION
TREATMENT PATTERNS OF CARE AND THE RISK OF SUBSEQUENT FRACTURES AMONG OSTEOPOROTIC WOMEN WITH INCIDENT FRACTURES
MODELLED COST-UTILITY ANALYSIS OF ROFECOXIB AND TRADITIONAL NON-STEROIDAL THERAPIES FOR TREATMENT OF CHRONIC OSTEOARTHRITIS
COST ANALYSIS OF A 12-WEEK CYCLE OF THERAPY WITH CELECOXIB VS. CONVENTIONAL NSAIDS IN PATIENTS WITH OSTEOARTHRITIS
AN ECONOMIC MODEL FOR GASTROINTESTINAL RISK STRATIFICATION COMPARING COX-2 INHIBITORS TO TRADITIONAL NSAIDS FOR ARTHRITIS TREATMENT
COST-EFFECTIVENESS OF BISPHOSPHONATE THERAPIES IN POST-MENOPAUSAL WOMEN
COST OFFSETS ARISING FROM THE USE OF MIACALCIN
FIRST-YEAR COSTS ASSOCIATED WITH NOVEL DISEASE-MODIFYING DRUGS IN THE TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS
AN ECONOMIC COMPARISON BETWEEN COX-2 INHIBITORS AND CONVENTIONAL NSAIDS IN THE TREATMENT PAIN RELATED TO ARTHRITIS
COST-EFFECTIVENESS OF PHARMACEUTICAL TREATMENTS OF FRACTURE IN WOMEN WITH ESTABLISHED OSTEOPOROSIS IN HONG KONG
COST-EFFECTIVENESS OF VARIOUS TREATMENT STRATEGIES IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS IN POLAND
WEB-BASED HEALTH STATUS ASSESSMENT OF A NATIONALLY REPRESENTATIVE SAMPLE OF ELDERLY OSTEOARTHRITIC PATIENTS
VALIDATION OF A PATIENT QUESTIONNAIRE TO ASSESS OSTEOPOROSIS-RELATED ATTITUDES, KNOWLEDGE AND BEHAVIOR
APPLICATION OF RASCH ANALYSIS IN COMPARISON OF SELF-ASSESSED HEALTH STATUS ACROSS TWO ARTHRITIS CONDITIONS USING A GENERIC HEALTH STATUS SURVEY
IMPACT OF ETANERCEPT FOR RHEUMATOID ARTHRITIS (RA) ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND FUNCTIONAL STATUS IN A NATURALISTIC SETTING
RISK OF CLINICAL DEPRESSION IN ARTHRITIS
STRENGTHS AND LIMITATIONS OF FUNCTIONAL HEALTH STATUS INSTRUMENTS FOR OSTEOARTHRITIS
CALCIUM SUPPLEMENTATION AND REDUCTION IN ASSOCIATED FRACTURES IN MEDICAID OSTEOPOROSIS PATIENTS
UTILIZATION CHARACTERISTICS OF COX-2 INHIBITORS IN A LARGE MANAGED CARE HEALTH PLAN
TRENDS OF ANTIRESORPTIVE THERAPIES USE AMONG WOMEN WITH PREVIOUS OSTEOPOROTIC FRACTURE
MISSED OPPORTUNITIES IN PHARMACEUTICAL TREATMENT OF OSTEOPOROSIS IN POST-FRACTURE WOMEN
REFILL ADHERENCE IN OSTEOPOROTIC WOMEN WITH PRIMARY AND SECONDARY FRACTURE PREVENTION
ANALYSIS OF NASAL STEROID DOSING PATTERNS IN A LARGE SAMPLE FROM A PRESCRIPTION DATABASE
PREVALENCE AND CORRELATES OF REDUCED PRODUCTIVITY ASSOCIATED WITH ALLERGIC RHINITIS IN THE WORKPLACE
COSTS OF ALLERGIC RHINITIS IN THE U.S
ESTIMATION AND COMPARISON OF LOSS IN PRODUCTIVITY BY THE HUMAN CAPITAL AND FRICTION COST APPROACH IN PATIENTS WITH ASTHMA
HEALTH CARE RESOURCES UTILIZATION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
ESTABLISHING THE RELIABILITY OF EVIDENCE FOR THE SIGNIFICANT IMPACT OF ALLERGIC RHINITIS ON HEALTH RELATED COSTS
ECONOMIC CONSEQUENCES OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN A NATIONAL SAMPLE OF US ADULTS
COSTS AND BENEFITS ASSOCIATED WITH INITIATION OF FLUTICASONE VERSUS MONTELUKAST AS CONTROLLER THERAPY IN A MEDICAID ASTHMATIC POPULATION
COSTS AND BENEFITS ASSOCIATED WITH ADDITION OF SALMETEROL VERSUS MONTELUKAST TO INHALED CORTICOSTEROID THERAPY IN A MEDICAID ASTHMATIC POPULATION
RESOURCE UTILIZATION FOR INPATIENT ASTHMA CARE IN CHILDREN AND ADULTS
COST-UTILITY ANALYSIS OF MIDDLE SEVERE ASTHMA WITH SODIUM CROMOGLYCATE AND SODIUM NEDOCROMIL
ESTIMATES OF THE COST OF ASTHMA IN A EMPLOYER POPULATION
THE COST OF ASTHMA IN CATALONIA
USE OF AN INTERACTIVE VOICE RESPONSE SYSTEM (IVRS) FOR LONG-TERM RESOURCE USE DATA COLLECTION
IMPACT OF ALLERGY AND ASTHMA BOTH SEPARATELY AND CONCOMITANTLY ON LOST HOURS FROM WORK
CULTURAL ADAPTATION AND VALIDATION OF CHILDHOOD ASTHMA QUESTIONNAIRE VERSION B (CAQ-B) FOR SINGAPORE CHILDREN
CLINICAL, PUBLIC HEALTH, AND ECONOMIC ISSUES ASSOCIATED WITH SWITCHING SECOND-GENERATION ANTIHISTAMINES FROM PRESCRIPTION TO OVER-THE-COUNTER
PREGNANCY OUTCOMES IN WOMEN TAKING ANTI-ASTHMATIC MEDICATIONS IN THE GEORGIA MEDICAID POPULATION
LONG-TERM BENEFITS OF CHEMOPREVENTIVE TAMOXIFEN AND ROUTINE MAMMOGRAPHY SCREENING IN WOMEN WHO ARE AT INCREASED RISK OF BREAST CANCER
AN INTERIM COST AND OUTCOME COMPARISON ALONGSIDE A PROSPECTIVE RANDOMIZED CLINICAL TRIAL COMPARING EARLY INTENSIFICATION WITH BONE MARROW TRANSPLANTATION (BMT) TO CONVENTIONAL DOSE CHEMOTHERAPY FOR PREVIOUSLY UNTREATED PATIENTS WITH AGGRESSIVE NON-HODGKIN'S LYMPHOMA
COLLECTION OF INFECTIOUS DISEASE AND ECONOMIC OUTCOMES FOR NON-HODGKIN'S LYMPHOMA AND MULTIPLE MYELOMA PATIENTS ADMITTED FOR INFECTIOUS COMPLICATIONS UTILIZING A PALM™ HANDHELD
RETROSPECTIVE COST ANALYSIS OF GEMZAR™ IN COMBINATION WITH CISPLATIN IN NON-SMALL CELL LUNG CANCER COMPARED TO OTHER COMBINATION THERAPIES IN GERMANY
PROSPECTIVE HEALTH ECONOMIC EVALUATION OF MEDICAL CARE FOR PATIENTS WITH MALIGNANT LYMPHOMAS IN GERMANY
FAMILY CAREGIVING COSTS FOR CANCER PATIENTS
COLORECTAL CANCER SCREENING
COST-EFFECTIVENESS ANALYSIS OF LHRH AGONISTS IN THE TREATMENT OF METASTATIC PROSTATE CANCER
PHARMACOECONOMIC ANALYSES OF AVAILABLE CHEMOTHERAPEUTIC AGENTS FOR THE MANAGEMENT OF ADVANCED COLORECTAL CANCER
WITHDRAWN
COSTS AND CHARACTERISTICS OF PATIENTS WHO UNDERGO BONE MARROW TRANSPLANT (BMT)
AN UPDATED RISK THRESHOLD MODEL FOR G-CSF PROPHYLAXIS USE IN CANCER CHEMOTHERAPY
COST-EFFECTIVENESS OF RITUXIMAB IN DIFFUSE LARGE B CELL LYMPHOMA
GENDER, FAMILY HISTORY AND OPTIMAL LIFETIME SCREENING PROGRAMS FOR COLORECTAL CANCER
CLINICAL AND ECONOMIC OUTCOMES ASSOCIATED WITH METASTATIC COLORECTAL CANCER IN MANAGED CARE POPULATIONS
EXCESS MORTALITY AND COSTS ASSOCIATED WITH SERIOUS FUNGAL INFECTIONS AMONG ELDERLY CANCER PATIENTS
SIDE EFFECTS OF CHEMOTHERAPY AMONG PATIENTS WITH OVARIAN CANCER
AN APPRAISAL OF TREATMENT SATISFACTION AND PATIENT PREFERENCE ASSESSMENTS IN PATIENTS DIAGNOSED WITH CANCER
USE OF THE EUROQOL VISUAL ANALOGUE SCALE IN ASSESSING LONGITUDINAL CHANGES IN QUALITY OF LIFE IN CANCER PATIENTS
ASSOCIATION OF INSURANCE COVERAGE AND EPIDEMIOLOGICAL RISK FACTORS ON GASTRIC CANCER SURGERY
WITHDRAWN
A RETROSPECTIVE COHORT STUDY OF DIABETES MELLITUS AND ANTIPSYCHOTIC TREATMENT IN THE UNITED KINGDOM
IMPROVEMENTS IN LIFE EXPECTANCY WITH LIFESTYLE CHANGES OR METFORMIN IN OVERWEIGHT, GLUCOSE INTOLERANT PATIENTS
OUTCOMES WITH ROSIGLITAZONE IN CLINICAL PRACTICE
THE ECONOMIC VALUE OF NON-DIHYDROPYRIDINE VS. DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER/ACE INHIBITOR COMBINATIONS IN PATIENTS WITH TYPE-II DIABETES
PREVENTION OF TYPE 2 DIABETES IN THE USA
FINANCIAL IMPACT OF IMPROVED DIABETES MANAGEMENT THROUGH BLOOD KETONE TESTING AND OPTIMIZED GLYCEMIC CONTROL
ECONOMIC COMPARISON OF SIX FIRST-LINE DRUG STRATEGIES IN TYPE 2 DIABETES USING A MONTE CARLO SIMULATION MODEL
A RETROSPECTIVE ANALYSIS OF SHORT-TERM COSTS AND UTLIZATION ASSOCIATED WITH GLYCEMIC CONTROL AMONG TYPE2 DIABETIC PATIENTS WITHIN A MANAGED CARE ORGANIZATION
INCIDENCE, MANAGEMENT AND COST OF CARDIO-VASCULAR AND RENAL COMPLICATIONS IN FRENCH TYPE 2 DIABETIC PATIENTS
HEALTH SERVICES COST AND UTILIZATION COMPARISONS AMONG LISPRO AND NON-LISPRO REGULAR INSULIN USERS
FACTORS PREDICTING SELF–RATED HEALTH AND PATIENT SATISFACTION IN A MANAGED CARE DIABETES POPULATION
TRENDS IN INSULIN THERAPY FOR TREATMENT OF TYPE-2 DIABETES MELLITUS
PATIENT'S PERSPECTIVE OF HYPOGLYCEMIA AS AN ADVERSE EFFECT OF ORAL ANTIDIABETIC MEDICATIONS
USING SURVIVAL MODELS TO PREDICT THE START OF INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
FROM HEALTH-RELATED QOL TO UTILITY—IS THERE A WAY?
ESTIMATING PREVALENCE AND SURVIVAL BY STAGE OF CANCER FROM THE US SEER DATABASE
DEVELOPMENT OF DESCRIPTIONS OF TREATMENTS FOR COLORECTAL CANCER FOR USE IN PREFERENCE MEASUREMENT
ASSESSING RESOURCE USE WITHIN ONCOLOGY INDICATIONS
FACTORS FOR THE VARIATION IN THE PREVALENCE OF ARTERIAL PERIPHRIAL DISEASE–STUDY IMPLICATIONS FOR OUTCOMES RESEARCH
ESTIMATING THE BENEFITS OF ANTIHYPERTENSIVE THERAPY
MODELING ON THE STOCHASTIC FRONTIER
VALIDATION OF COST ESTIMATION TECHNIQUE FOR HOSPITALIZATIONS FOR USE IN MULTINATIONAL ECONOMIC EVALUATIONS
THE RELATIONSHIP BETWEEN DISEASE AREA AND TYPE OF ECONOMIC STUDY–DOES IT EXIST?
DANCING WITH THE DEVIL
LIFE YEARS LOST DUE TO CHD
DEVELOPMENT OF A NUTRITION QUALITY OF LIFE MEASURE
STANDARD GAMBLE AND CONJOINT UTILITY WEIGHTS
THE DEVELOPMENT OF A SEVERITY STAGING SYSTEM FOR ECONOMIC EVALUATIONS OF THE PROGRESSION OF GLAUCOMA
MATHEMATICAL MODEL (MM) OF ANTIBIOTIC (AB) IN VITRO SUSCEPTIBILITY (SUS) OVER THE COMPLETE RANGE OF MINIMUM INHIBITORY CONCENTRATION (MIC)
USE OF VARIOUS METHODS FOR COST ESTIMATION IN MULTI-NATIONAL ECONOMIC EVALUATIONS
METHODS FOR ASSESSING THE VALUE OF ANTIPSYCHOTIC TREATMENT
PERFORMING EPIDEMIOLOGICAL STUDIES IN SCHIZOPHRENIA
THE USE OF PHARMACY CLAIMS DATA TO EVALUATE QUALITY OF PHARMACOLOGIC CARE FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER
TRENDS IN PEDIATRIC HEALTH ECONOMIC EVALUATION
EVALUATING HEALTH PLAN MANAGEMENT OF EMPLOYER INDIRECT COSTS
ITEM REDUCTION OF A NEW PHARMACEUTICAL THERAPY RELATED QUALITY OF LIFE (PTRQOL) INSTRUMENT
THE ODDS OF BENEFIT VERSUS NON-BENEFIT OF THERAPY ASSOCIATED WITH THE NUMBER NEEDED TO TREAT
JUSTIFYING THE USE OF COST MINIMIZATION ANALYSIS
THE STATUS OF QUALITY OF LIFE DATA IN HEALTH TECHNOLOGY ASSESSMENTS
FEATURES OF GOMPERTZ FUNCTIONS IN MODELING MORTALITY RATES
A UTILITY-MAXIMISATION MODEL OF CHOICE BETWEEN MEDICAL INTERVENTIONS INVOLVING RISK
ELECTRONIC DATA COLLECTION OF PATIENT-REPORTED OUTCOMES
PATIENT-GENERATED OUTCOMES
A TWO-DIMENSIONAL MARKOV MODEL WITH DIFFERENT CYCLE LENGTHS FOR A CHRONIC CONDITION WITH SLOW IRREVERSIBLE DISEASE PROGRESSION AND RECURRENT PERIODS OF SEVERE SYMPTOMS
PSYCHOMETRIC PROPERTIES OF THE HEALTH RELATED QUALITY OF LIFE INSTRUMENT IN THE MEDICAL EXPENDITURE PANEL SURVEY
EVALUATING THE USE OF PROBABILISTIC SENSITIVITY ANALYSIS VIA MONTE CARLO SIMULATION (MCS)
LITERATURE REVIEW OF GUIDELINES FOR CROSS-CULTURAL ADAPTATION OF HRQL MEASURES
A LOGICAL PROBLEM IN VIEWING UTILITY THEORY AS NORMATIVE
WITHDRAWN
INCORPORATING JAPAN INTO GLOBAL OUTCOMES RESEARCH PROTOCOLS
INTEGRATION OF INTERNATIONAL INPUT INTO INSTRUMENT DESIGN
EVALUATING THE STRUCTURE OF PHARMACOECONOMIC FELLOWSHIP PROGRAMS
THE USE OF DRG-RELATED DATA ON KNEE PROCEDURES IN THE ANALYSIS OF UTILISATION OF RESOURCES BETWEEN BELGIAN HOSPITALS
THE POTENTIAL IMPORTANCE OF DATA SOURCES AND ANALYTIC APPROACHES TO THE EXTERNAL VALIDITY OF ECONOMIC STUDIES
SATISFACTION WITH SMOKING CESSATION TREATMENTS–A SYSTEMATIC REVIEW OF THE DIMENSIONS
DESIGN AND VALIDITY OF AUTOMATED HEALTH CARE DATA SCREENS TO DETECT IN-HOSPITAL ADVERSE DRUG EVENTS
USEFULNESS OF ELECTRONIC COMPLIANCE DATA IN AN EFFECTIVENESS TRIAL
ESTABLISHING THE EXPECTED RATE OF COGNITIVE DECLINE IN ALZHEIMER'S DISEASE
ANTIPSYCHOTIC AGENTS AND THE RISK OF DEVELOPING DIABETES
SUPPLEMENTAL ANALYSIS OF THE QUETIAPINE EXPERIENCE WITH SAFETY AND TOLERABILITY (QUEST) STUDY
EFFICACY OF NURSE TELEHEALTH CARE AND PEER SUPPORT IN AUGMENTING TREATMENT OF DEPRESSION IN PRIMARY CARE
RISK OF DIABETES FOR INDIVIDUALS WITH SCHIZOPHRENIA TREATED WITH ANTIPSYCHOTICS
OUTCOMES AND COST OF TREATMENT WITH RISPERIDONE VERSUS OLANZAPINE AMONG PATIENTS WITH CHRONIC SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDERS
ONE YEAR HOSPITALIZATION RATES IN PATIENTS WITH SCHIZOPHRENIA DURING LONG-TERM TREATMENT WITH LONG-ACTING RISPERIDONE
THE DIRECT AND INDIRECT ECONOMIC COSTS OF PSYCHOTIC DISORDERS TO BOTH PATIENTS AND CAREGIVERS
THE BURDEN OF DEPRESSION IN CANADA
A SWEDISH PHARMACOECONOMIC EVALUATION OF ESCITALOPRAM, A NEW SSRI
EMPLOYMENT-RELATED COSTS OF INFORMAL CAREGIVING FOR ALZHEIMER'S DISEASE PATIENTS
IMPACT OF ANXIETY ON ABSENTEEISM
HEALTH CARE EXPENDITURES OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER AND POST TRAUMATIC STRESS DISORDER
PREVALENCE AND COSTS OF TREATMENT-RESISTANT DEPRESSION IN A CANADIAN CLAIMS DATABASE
PREVALENCE AND COSTS OF ACCIDENTS AMONG ATTENTION-DEFICIT/HYPERACTIVITY DISORDER PATIENTS
ECONOMICS OF PERSISTENCE WITH INITIALLY PRESCRIBED ANTIPSYCHOTIC IN OLDER PSYCHOTIC PATIENTS AND IN PATIENTS WITH BIPOLAR DISORDER
UTILIZATION AND COST OF RESOURCES IN BIPOLAR PATIENTS RECEIVING ATYPICAL ANTIPSYCHOTICS
USING A COMMUNITY SAMPLE TO DERIVE UTILITY VALUES OF SCHIZOPHRENIA TREATMENT OUTCOMES FROM A TIME TRADE-OFF METHODOLOGY
WITHDRAWN
INPATIENT MEDICATION UTILIZATION AND COSTS OF RISPERIDONE, OLANZAPINE AND QUETIAPINE
ECONOMIC OUTCOMES ASSOCIATED WITH OLANZAPINE VERSUS DIVALPROEX TREATMENT FOR ACUTE MANIA
THE COST CONSEQUENCES OF CONTINUED TREATMENT-RESISTANCE IN DEPRESSION
MODELING THE ECONOMIC IMPACT OF GALANTAMINE TREATMENT IN PATIENTS WITH ALZHEIMER'S DISEASE IN DIFFERENT HEALTH CARE SYSTEMS
COST IMPACT OF DEPOT DOSAGE FORMS OF ATYPICAL VERSUS TYPICAL ANTIPSYCHOTICS
A COMPARISON OF RISPERIDONE AND OLANZAPINE MENTAL HEALTH COSTS FOR MANAGED CARE PATIENTS WITH SCHIZOPHRENIA
SCHIZOPHRENIA CARE AND ASSESSMENT PROGRAM (SCAP)
IS DONEPWEZIL COST-EFFECTIVE IN THE TREATMENT OF ALZHEIMMER' DISEASE (AD?)
THE EFFECTS OF PANAX GINSENG ON QUALITY OF LIFE
INFLUENCE OF CAREGIVING ON HEALTH STATUS OF DEMENTIA CAREGIVERS
CATEGORICAL RESPONSE DEFINES TREATMENT EFFECTIVENESS OF OLANZAPINE VERSUS RISPERIDONE IN THE IMPROVEMENT OF NEGATIVE SYMPTOMS AND QUALITY OF LIFE IN SCHIZOPHRENIA
THE IMPACT OF DULOXETINE FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER ON THE QUALITY OF LIFE IN DEPRESSION SCALE
QUALITY OF LIFE IN SCHIZOPHRENIA
PSYCHOMETRIC EVALUATION OF THE MODIFIED STRAIN IN NURSING CARE ASSESSMENT SCALE
LABOR SUPPLY OF POOR RESIDENTS IN METROPOLITAN MIAMI
IMPACT OF PRIMARY PAYER TYPE ON ACCESS TO ANTIDEPRESSANT PHARMACOTHERAPY AMONG PATIENTS DIAGNOSED WITH DEPRESSION
WITHDRAWN
CLINICAL COMPARABILITY OF SCHIZOPHRENIA PATIENTS SERVED AT TWO PUBLIC SETTINGS
BASELINE COMPARISON OF PATIENTS WITH SCHIZOPHRENIA USING OLANZAPINE, RISPERIDONE AND TYPICAL ANTIPSYCHOTICS IN CALIFORNIA MEDICAID PROGRAM
THE IMPACT OF SECOND-GENERATION ANTIPSYCHOTICS IN BIPOLAR PATIENTS IN THE CALIFORNIA MEDICAID PROGRAM
REDUCTION IN LONG-ACTING BENZODIAZEPINE THERAPY AND ASSOCIATED FRACTURES IN ELDERLY MEDICAID PATIENTS
FROM CONVENTIONAL ANTIPSYCHOTICS TO ATYPICALS AND BACK
THE IMPACT OF A FORMULARY EXPANSION TO INCLUDE ADDITION OF SECOND-GENERATION ANTIPSYCHOTIC MEDICATIONS ON THE TREATMENT OF PATIENTS WITH SCHIZOPHRENIA
SURVEY AND STATED PREFERENCE TECHNIQUES FOR ESTIMATING THE DEMAND FOR ALCOHOLISM MEDICATIONS
THE EFFECT OF SCHIZOPHRENIA SYMPTOMS ON EMPLOYMENT OUTCOMES
MEDICATION TREATMENT PATTERNS FOLLOWING THE INITIATION OF OLANZAPINE VERSUS RISPERIDONE IN A NATURALISTIC SETTING
QUANTIFYING POTENTIALLY INAPPROPRIATE OPHTHALMIC BETA-BLOCKER USE IN THE MANAGEMENT OF GLAUCOMA
A DECISION-ANALYTIC MODEL TO COMPARE THE COST OF METHYL AMINOLEVULINATE PHOTODYNAMIC THERAPY WITH STANDARD TREATMENTS IN THE UK FOR DIFFICULT-TO-TREAT BASAL CELL CARCINOMA AND ACTINIC KERATOSIS
TOPICAL CORITCOSTEROID AND PHYSICIAN VISIT UTILIZATION AND COSTS IN PATIENTS WITH ATOPIC DERMATITIS
INFORMAL CAREGIVERS COSTS IN THE ELDERLY US POPULATION
COST ANALYSIS OF ISOTRETINOIN FOR SEVERE RECALCITRANT NODULAR ACNE
COST EFFECTIVENESS OF PHOTODYNAMIC THERAPY (PDT) WITH VERTEPORFIN IN THE UK
ECONOMIC EVALUATION OF PHOTODYNAMIC THERAPY WITH VERTEPORFIN FOR PREDOMINANTLY CLASSIC, SUBFOVEAL CNV SECONDARY TO AGE-RELATED MACULAR DEGENERATION
THE PATIENTS' PERCEPTION OF THEIR PSORIASIS AND ITS TREATMENT THROUGH A DIARY
PSORIASIS AND EVERYDAY LIFE
THE PSORIASIS MANAGEMENT DURATION INDUCED DIFFERENCES IN THE DISABILTY'S REPERCUSSION
FUNCTIONAL LIMITATIONS IN THE US ELDERLY POPULATION WITH VARYING LEVELS OF VISUAL IMPAIRMENT
ANTIHISTAMINE UTILIZATION AND COSTS IN PATIENTS WITH ATOPIC DERMATITIS
EFFECTIVENESS OF MEDICAL INTERVENTIONS IN PATIENTS WITH SYMPTOMS OF GERD—A SYSTEMATIC REVIEW
THERAPEUTIC COMPARABILITY OF PROTON PUMP INHIBITORS
IMPACT OF PROTON PUMP INHIBITOR UTILIZATION PATTERNS ON GASTROESOPHAGEAL REFLUX DISEASE-RELATED COSTS
WITHDRAWN
COST-EFFECTIVENESS OF IV PPI'S IN THE TREATMENT OF NON-VARICEAL UPPER GI BLEEDING FOLLOWING URGENT ENDOSCOPY
EFFECT OF POSTOPERATIVE ILEUS ON LENGTH OF STAY IN COLECTOMY
ECONOMIC OUTCOMES OF EMPLOYER BENEFICIARIES TREATED FOR IRRITABLE BOWEL SYNDROME (IBS)
A COST ANALYSIS OF DIAGNOSTIC AND TREATMENT STRATEGIES IN PATIENTS WITH SYMPTOMS OF POUCHITIS
THE COST-EFFECTIVENESS OF INTRAVENOUS PROTON PUMP INHIBITOR CONTINUOUS INFUSION (IV PPI) ADMINISTERED PRIOR TO ENDOSCOPY IN THE TREATMENT OF PATIENTS WITH NON-VARICEAL UPPER GI BLEEDING
PHARMACY DISPENSING PATTERNS, COST AND HEALTHCARE UTILIZATION
EFFECT OF RABEPRAZOLE ON HEALTHRELATED QUALITY OF LIFE (HRQOL) IN PATIENTS REPORTING INEFFECTIVE RELIEF WITH PRIOR OMEPRAZOLE OR LANSOPRAZOLE THERAPY
FACTOR STRUCTURE AND FURTHER VALIDATION OF THE GASTROESOPHAGEAL REFLUX DISEASE (GERD) SYMPTOM ASSESSMENT SCALE
USE OF NONSTEROIDAL ANTI-INFLAMMATORY AGENTS IN PATIENTS AT HIGH RISK FOR GASTROINTESTINAL SIDE EFFECTS IN A VETERANS AFFAIRS MEDICAL CENTER
ASSESSMENT OF USE OF THE VETERANS AFFAIRS' CRITERIA FOR NONSTEROIDAL ANTI-INFLAMMATORY AGENTS
THE EFFECT OF ANTIBIOTIC USE ON RETURN VISITS FOR ACUTE RESPIRATORY TRACT INFECTIONS
RETROSPECTIVE ANALYSIS OF IMIPENEM/CILASTIN VERSUS PIPRACILLIN/TAZOBACTAM IN TREATMENT OF INFECTED NEUTROPENIC PATIENTS
COST-EFFECTIVENESS OF VACCINE DEVELOPMENT AND ENVIRONMENTAL CONTROL AGAINST DENGUE IN SOUTHEAST ASIA
ECONOMIC IMPACT OF RESPIRATORY SYNCYTIAL VIRUS INFECTION ON HEALTHCARE RESOURCE UTILIZATION AND COSTS IN THE UNITED STATES
COST-EFFECTIVENESS OF VACCINATING ADULT CLOSE CONTACTS WITH BOOSTRIX®
DIRECT MEDICAL COSTS OF MANAGING AN EPISODE OF RESPIRATORY SYNCYTIAL VIRUS (RSV) COMMUNITY ACQUIRED PNEUMONIA (CAP) IN U.S. ADULTS
EVALUATION OF THE COST-EFFECTIVENESS OF AZITHROMYCIN VERSUS AMOXICILLIN, AMOXICILLIN/CLAVULANATE, AND CLARITHROMYCIN FOR THE TREATMENT OF ACUTE SINUSITIS IN A LARGE MANAGED CARE DATABASE
INCIDENCE AND RELATED HEALTHCARE RESOURCE USE OF RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION IN A HIGH-RISK ADULT POPULATION
LONG-TERM ECONOMIC CONSEQUENCES OF ORGAN DYSFUNCTION FOLLOWING HOSPITAL DISCHARGE OF SEPSIS PATIENTS
COST-UTILITY OF SELECTIVE BUPRENORPHINE SUBSTITUTION FOR METHADONE MAINTENANCE IN PREVENTING HIV TRANSMISSION
INITIAL ANTIMICROBIAL THERAPY AND OUTCOMES IN PATIENTS HOSPITALIZED WITH COMMUNITY-ACQUIRED PNEUMONIA (CAP)
COSTS OF TREATMENT FOR AMBULATORY LOWER RESPIRATORY TRACT INFECTION IN QUEBEC SENIORS
THE IMPACT OF ANTIBIOTIC SELECTION ON TREATMENT OUTCOMES FOR ACUTE OTITIS MEDIA
HEALTH RESOURCE UTILIZATION IN THE TREATMENT OF ACUTE BACTERIAL SINUSITIS
PREFERENCES AND WILLINGNESS-TO-PAY FOR HEALTH STATES PREVENTED BY PNEUMOCOCCAL CONJUGATE VACCINE
AN ECONOMIC ASSESSMENT OF THE IMPACT OF ESCHERICHIA COLI RESISTANCE TO TRIMETHOPRIM-SULFAMETHOXAZOLE IN THE TREATMENT OF URINARY TRACT INFECTION
PRELIMINARY RESULTS OF A U.S.-BASED STUDY TO VALIDATE THE ACUTE BRONCHITIS SYMPTOM SEVERITY SCALE
THE ASSOCIATION BETWEEN HEALTH RELATED QUALITY OF LIFE AND ADHERENCE TO THERAPY IN HEPATITIS C
PRESCRIBING DECISIONS IN A UTILITY MODEL
PHYSICIAN PRESCRIBING PATTERNS FOR PEDIATRIC OTITIS MEDIA IN AMBULATORY PATIENTS
SECOND-LINE THERAPY FOR OUTPATIENT TREATMENT FOR COMMUNITY-ACQUIRED PNEUMONIA
PATIENT TREATMENT ACCORDING TO PRACTICE GUIDELINES IN COMMUNITY HOSPITALS COMPARED TO TEACHING HOSPITALS IN THE COMMUNITY-ACQUIRED PNEUMONIA (CAP) PROJECT
THE IMPACT OF PHYSICIAN REPORTED RISK FACTORS ON HOSPITALIZATION RATES FOR INFANTS ON PALIVIZUMAB THERAPY
WHAT IS THE VALUE OF WARD SUPPLY DATA FOR MONITORING ANTIBIOTIC USE IN HOSPITAL?
LIFE EXPECTANCY PREDICTION OF HRT FOR PRIMARY PREVENTION STRATEGIES IN POST-MENOPAUSAL WOMEN
ECONOMIC ANALYSIS OF SILDENAFIL CITRATE ADD-ON TO TREAT SSRI-INDUCED ERECTILE DYSFUNCTION
COVERAGE OF SILDENAFIL CITRATE BY EMPLOYERS AND HEALTH PLANS
DEVELOPING A BETTER UNDERSTANDING OF COST-EFFECTIVENESS OF HORMONE REPLACEMENT THERAPY (HRT)
COST-EFFECTIVENESS ANALYSIS OF CURRENTLY MARKETED LONG-TERM CONTRACEPTIVES
COST EFFECTIVENESS MODELING COMPARING RECOMBINANT FSH WITH URINARY FSH FOR OVARIAN STIMULATION—A MULTINATIONAL EVALUATION
IDENTIFYING PATIENT AND HOSPITAL-RELATED PREDICTORS OF MATERNITY LENGTH OF STAY AND TOTAL INPATIENT CHARGES FOR OBSTETRICAL DELIVERIES IN A NATIONAL SAMPLE
BENIGN PROSTATIC HYPERPLASIA
BENIGN PROSTATIC HYPERPLASIA
SOCIO-ECONOMIC IMPACT OF MIGRAINE IN FRANCE IN 2000
COST-EFFECTIVENESS OF RAPID MRI VERSUS LUMBAR X-RAY AS THE INITIAL INVESTIGATION FOR PRIMARY CARE PATIENTS WITH LOW BACK PAIN
COST-BENEFIT ANALYSIS OF ALMOTRIPTAN FROM A SOCIETAL PERSPECTIVE, USING CLINICAL TRIAL OUTCOMES
PRESCRIBING PATTERNS OF LONG-ACTING OPIOIDS FOR CHRONIC NON-MALIGNANT PAIN IN THE VETERANS ADMINISTRATION SYSTEM
A CONJOINT EXERCISE WITH PHYSICIANS, PATIENTS AND MCO FORMULARY MANAGERS
WHAT IS IMPACT OF INSOMNIA ON MEDICAL DISORDERS, QUALITY OF LIFE AND ABSENTEEISM? A STUDY IN A FRENCH WORKING POPULATION
THE MIGRAINE IN FRANCE IN 2000
MULTIPLE SCLEROSIS
TRIPTAN UTILIZATION PATTERNS IN A MANAGED CARE POPULATION
THE STATE OF ANTI-EPILEPTIC DRUG PRESCRIBING
A COMPARISON OF PD AND HD PATIENT SURVIVAL ALLOWING FOR SWITCHES FROM PD TO HD
UTILIZATION PATTERNS ASSOCIATED WITH TOLTERODINE IMMEDIATE RELEASE VERSUS OXYBUTYNIN IN THE MANAGEMENT OF URINARY INCONTINENCE (UI)
COST EFFECTIVENESS OF INTENSIVE BEHAVIORAL MANAGEMENT VERSUS DDAVP IN PRIMARY NOCTURNAL ENURESIS
AN ECONOMIC MODEL OF OVERACTIVE BLADDER IN NORWAY
INCIDENCE AND COST ASSOCIATED WITH PHARMACOLOGICAL TREATMENT FOR EMPLOYEES DIAGNOSED WITH URINARY AND OVERACTIVE BLADDER DISORDERS
A BUDGET IMPACT ANALYSIS OF EARLY REFERRAL TO A NEPHROLOGIST FOR ELDERLY MEDICARE PATIENTS WITH END-STAGE RENAL DISEASE
DEVELOPMENT OF THE SYMPTOM FREQUENCY AND BOTHERSOMENESS SCALE FOR STRESS URINARY INCONTINENCE (SFB-SUI)
VALIDATION OF THE PERCEPTION OF BLADDER CONDITION MEASURE IN OVERACTIVE BLADDER
VALIDATION OF THE URGENCY PERCEPTION SCALE
ASSESSING PATIENT SATISFACTION IN A DIALYSIS POPULATION
EFFECTS OF LONG-TERM TOLTERODINE TREATMENT ON PHYSICAL AND SYMPTOM ASPECTS OF HEALTH-RELATED QUALITY OF LIFE IN OVERACTIVE BLADDER PATIENTS
HOW RESPONSIVE IS THE OVERACTIVE BLADDER QUESTIONNAIRE (OAB-Q) TO CHANGES IN URGENCY, FREQUENCY, AND INCONTINENCE?